149 Fifth Avenue
Suite 500
New York, NY 10010
United States
212 994 8250
https://minktherapeutics.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 31
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Garo H. Armen Ph.D. | Executive Chairman | N/A | N/A | 1953 |
Dr. Jennifer S. Buell Ph.D. | President, CEO & Director | 916,75k | N/A | 1976 |
Dr. Marcus Antonius van Dijk Ph.D. | Chief Scientific Officer | 458,28k | N/A | 1962 |
Ms. Christine M. Klaskin | Treasurer | 29,62k | N/A | 1966 |
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
MiNK Therapeutics, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.